Glycoprotein IIb/IIIa inhibitors: The resurgence of tirofiban

Vascular Pharmacology

Volumn 78, Issue , 2016, Pages 10-16

  King, Shawn ^a   Short, Marintha ^a   Harmon, Cassidy ^a  

^a Saint Joseph Hospital Lexington   (United States)

Author keywords

Abciximab (ab SIKS ih mab); Eptifibatide (ep ti FIB ih tide); Tirofiban (tye roe FYE ban)

Indexed keywords

ABCIXIMAB; CLOPIDOGREL; EPTIFIBATIDE; FIBRINOGEN RECEPTOR; LOW MOLECULAR WEIGHT HEPARIN; TIROFIBAN; ANTITHROMBOCYTIC AGENT; IMMUNOGLOBULIN F(AB) FRAGMENT; MONOCLONAL ANTIBODY; PEPTIDE; TYROSINE;

ANTIINFLAMMATORY ACTIVITY; BARE METAL STENT; BINDING AFFINITY; BLEEDING TIME; BLOOD CLOTTING; CONFORMATIONAL TRANSITION; CONTINUOUS INFUSION; CORONARY ARTERY RECANALIZATION; DRUG APPROVAL; DRUG EFFICACY; DRUG EXCRETION; DRUG HALF LIFE; DRUG SAFETY; GASTROINTESTINAL HEMORRHAGE; HEART MUSCLE REVASCULARIZATION; HUMAN; NON ST SEGMENT ELEVATION ACUTE CORONARY SYNDROME; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PRIORITY JOURNAL; REVIEW; SIROLIMUS ELUTING CORONARY STENT; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; THROMBOCYTE AGGREGATION; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; ACUTE CORONARY SYNDROME; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; PATHOPHYSIOLOGY; PRACTICE GUIDELINE; THROMBOSIS;

ACUTE CORONARY SYNDROME; ANTIBODIES, MONOCLONAL; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; PEPTIDES; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; PRACTICE GUIDELINES AS TOPIC; THROMBOSIS; TYROSINE;

EID: 84959144361     PISSN: 15371891     EISSN: 18793649     Source Type: Journal    
DOI: 10.1016/j.vph.2015.07.008     Document Type: Review

References (54)

1. Seligsohn U. Glanzmann thrombasthenia: a model disease which paved the way to powerful therapeutic agents. Pathophysiol. Haemost. Thromb. 2002, 32(5-6):216-217.
2. Braunwald's Heart Disease: a Textbook of Cardiovascular Medicine 2012, Elsevier Saunders, Philadelphia. 9th ed.
3. Wishart D.S., Knox C., Guo A.C., Cheng D., Shrivastava S., Tzur D., Gautam B., Hassanali M. DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res 2008 Jan, 36(Database issue):D901-D906.
4. Integrilin [package insert] 2014, Merck & Co. Inc., Whitehouse Station, NJ.
5. Aggrastat [package insert] 2015, Medicure Pharma, Inc., Somserset, NJ.
6. Jneid H., Anderson J.L., Wright R.S., et al. 2012 ACCF/AHA focused update of the guideline for the management of patients with unstable angina/non-ST-elevation myocardial infarction (updating the 2007 guideline and replacing the 2011 focused update): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J. Am. Coll. Cardiol. 2012, 60(7):645-681.
7. Amsterdam E.A., Wenger N.K., Brindis R.G., et al. 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2014, 130(25):2354-2394.
8. O'Gara P.T., Kushner F.G., Ascheim D.D., et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2013, 127(4):529-555.
9. Levine G.N., Bates E.R., Blankenship J.C., et al. ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. J. Am. Coll. Cardiol. 2011, 58(24):e44-122.
10. Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. Lancet 1998, 352(9122):87-92.
11. Topol E.J., Moliterno D.J., Herrmann H.C., et al. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization. N. Engl. J. Med. 2001, 344(25):1888-1894.
12. Akerblom A., James S.K., Koutouzis M., et al. Eptifibatide is noninferior to abciximab in primary percutaneous coronary intervention: results from the SCAAR (Swedish Coronary Angiography and Angioplasty Registry). J. Am. Coll. Cardiol. 2010, 56(6):470-475.
13. De Luca G., Ucci G., Cassetti E., Marino P. Benefits from small molecule administration as compared with abciximab among patients with ST-segment elevation myocardial infarction treated with primary angioplasty: a meta-analysis. J. Am. Coll. Cardiol. 2009, 53(18):1668-1673.
14. Gurm H.S., Smith D.E., Collins J.S., et al. The relative safety and efficacy of abciximab and eptifibatide in patients undergoing primary percutaneous coronary intervention: insights from a large regional registry of contemporary percutaneous coronary intervention. J. Am. Coll. Cardiol. 2008, 51(5):529-535.
15. Zeymer U., Margenet A., Haude M., et al. Randomized comparison of eptifibatide versus abciximab in primary percutaneous coronary intervention in patients with acute ST-segment elevation myocardial infarction: results of the EVA-AMI Trial. J. Am. Coll. Cardiol. 2010, 56(6):463-469.
16. Windecker S., Kolh P., Alfonso F., et al. 2014 ESC/EACTS Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS)Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur. Heart J. 2014, 35(37):2541-2619.
17. Mascelli M.A., Lance E.T., Damaraju L., Wagner C.L., Weisman H.F., Jordan R.E. Pharmacodynamic profile of short-term abciximab treatment demonstrates prolonged platelet inhibition with gradual recovery from GP IIb/IIIa receptor blockade. Circulation 1998, 97(17):1680-1688.
18. Pinto D.S., Kirtane A.J., Ruocco N.A., et al. Administration of intracoronary eptifibatide during ST-elevation myocardial infarction. Am. J. Cardiol. 2005, 96(11):1494-1497.
19. Namazi M.H., Safi M., Vakili H., Saadat H., Karimi E., Bagheri R.K. Comparison between intracoronary abciximab and intravenous eptifibatide administration during primary percutaneous coronary intervention of acute ST-segment elevation myocardial infarction. J. Tehran Heart Cent. 2013, 8(3):132-139.
20. Windecker S., Kolh P., Alfonso F., et al. 2014 ESC/EACTS guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur. Heart J. 2014, 35(37):2541-2619.
21. Aster R.H., Curtis B.R., Bougie D.W., et al. Thrombocytopenia associated with the use of GPIIb/IIIa inhibitors: position paper of the ISTH working group on thrombocytopenia and GPIIb/IIIa inhibitors. J. Thromb. Haemost. 2006, 4(3):678-679.
22. Merlini P.A., Rossi M., Menozzi A., et al. Thrombocytopenia caused by abciximab or tirofiban and its association with clinical outcome in patients undergoing coronary stenting. Circulation 2004, 109(18):2203-2206.
23. Llevadot J., Coulter S.A., Giugliano R.P. A practical approach to the diagnosis and management of thrombocytopenia associated with glycoprotein IIb/IIIa receptor inhibitors. J. Thromb. Thrombolysis 2000, 9(2):175-180.
24. Sarode R. How do I transfuse platelets (PLTs) to reverse anti-PLT drug effect?. Transfusion 2012, 52(4):695-701. (quiz 694).
25. Berkowitz S.D., Harrington R.A., Rund M.M., Tcheng J.E. Acute profound thrombocytopenia after C7E3 Fab (abciximab) therapy. Circulation 1997, 95(4):809-813.
26. Bougie D.W., Wilker P.R., Wuitschick E.D., et al. Acute thrombocytopenia after treatment with tirofiban or eptifibatide is associated with antibodies specific for ligand-occupied GPIIb/IIIa. Blood 2002, 100(6):2071-2076.
27. Paradiso-Hardy F.L., Madan M., Radhakrishnan S., Hurden S., Cohen E.A. Severe thrombocytopenia possibly related to readministration of eptifibatide. Catheter. Cardiovasc. Interv. 2001, 54(1):63-67.
28. Stone G.W., Witzenbichler B., Guagliumi G., et al. Bivalirudin during primary PCI in acute myocardial infarction. N. Engl. J. Med. 2008, 358(21):2218-2230.
29. Fung A.Y., Saw J., Starovoytov A., et al. Abbreviated infusion of eptifibatide after successful coronary intervention: the BRIEF-PCI (Brief Infusion of Eptifibatide Following Percutaneous Coronary Intervention) randomized trial. J. Am. Coll. Cardiol. 2009, 53(10):837-845.
30. Valgimigli M., Tebaldi M., Campo G., et al. Prasugrel versus tirofiban bolus with or without short post-bolus infusion with or without concomitant prasugrel administration in patients with myocardial infarction undergoing coronary stenting: the FABOLUS PRO (Facilitation through Aggrastat By drOpping or shortening Infusion Line in patients with ST-segment elevation myocardial infarction compared to or on top of PRasugrel given at loading dOse) trial. JACC Cardiovasc. Interv. 2012, 5(3):268-277.
31. Shahzad A., Kemp I., Mars C., et al. Unfractionated heparin versus bivalirudin in primary percutaneous coronary intervention (HEAT-PPCI): an open-label, single centre, randomised controlled trial. Lancet 2014, 384(9957):1849-1858.
32. Bhatt D.L., Stone G.W., Mahaffey K.W., et al. Effect of platelet inhibition with cangrelor during PCI on ischemic events. N. Engl. J. Med. 2013, 368(14):1303-1313.
33. Kalra K., Franzese C.J., Gesheff M.G., et al. Pharmacology of antiplatelet agents. Curr. Atheroscler. Rep. 2013, 15(12):371.
34. Webb G.J., Swinburn J.M., Grech H. Profound delayed thrombocytopenia presenting 16 days after abciximab (Reopro(R)) administration. Platelets 2011, 22(4):302-304.
35. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. The EPIC investigation. N. Engl. J. Med. 1994, 330(14):956-961.
36. Tcheng J.E., Kandzari D.E., Grines C.L., et al. Benefits and risks of abciximab use in primary angioplasty for acute myocardial infarction: the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial. Circulation 2003, 108(11):1316-1323.
37. Lemmer J.H., Vlahakes G.J. Handbook of Patient Care in Cardiac Surgery 2010, Lippincott Williams & Wilkins, Philadelphia, PA. 7th ed.
38. A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM) study investigators. N. Engl. J. Med. 1998, 338(21):1498-1505.
39. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. The PURSUIT trial investigators. Platelet glycoprotein IIb/IIIa in unstable angina: receptor suppression using integrilin therapy. N. Engl. J. Med. 1998, 339(7):436-443.
40. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) study investigators. N. Engl. J. Med. 1998, 338(21):1488-1497.
41. Moliterno D.J. A randomized two-by-two comparison of high-dose bolus tirofiban versus abciximab and unfractionated heparin versus bivalirudin during percutaneous coronary revascularization and stent placement: the tirofiban evaluation of novel dosing versus abciximab with clopidogrel and inhibition of thrombin (TENACITY) study trial. Catheter Cardiovasc. Interv. 2011, 77(7):1001-1009.
42. Valgimigli M., Campo G., Percoco G., et al. Comparison of angioplasty with infusion of tirofiban or abciximab and with implantation of sirolimus-eluting or uncoated stents for acute myocardial infarction: the MULTISTRATEGY randomized trial. JAMA 2008, 299(15):1788-1799.
43. Nazif T.M., Mehran R., Lee E.A., et al. Comparative effectiveness of upstream glycoprotein IIb/IIIa inhibitors in patients with moderate- and high-risk acute coronary syndromes: an Acute Catheterization and Urgent Intervention Triage Strategy (ACUITY) substudy. Am. Heart J. 2014, 167(1):43-50.
44. Stone G.W., Bertrand M.E., Moses J.W., et al. Routine upstream initiation vs deferred selective use of glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: the ACUITY Timing trial. JAMA 2007, 297(6):591-602.
45. Valgimigli M., Biondi-Zoccai G., Tebaldi M., et al. Tirofiban as adjunctive therapy for acute coronary syndromes and percutaneous coronary intervention: a meta-analysis of randomized trials. Eur. Heart J. 2010, 31(1):35-49.
46. Manoukian S.V. A Randomized, Multicenter, Open-Label Study to Evaluate the Efficacy of Tirofiban Using a High-Dose Bolus Plus a Shortened Infusion Duration Versus Label-Dosing Eptifibatide in Patients Undergoing Percutaneous Coronary Intervention 2016.
47. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N. Engl. J. Med. 1997, 336(24):1689-1696.
48. International, randomized, controlled trial of lamifiban (a platelet glycoprotein IIb/IIIa inhibitor), heparin, or both in unstable angina. The PARAGON Investigators. Platelet IIb/IIIa antagonism for the reduction of acute coronary syndrome events in a global organization network. Circulation 1998, 97(24):2386-2395.
49. Giugliano R.P., White J.A., Bode C., et al. Early versus delayed, provisional eptifibatide in acute coronary syndromes. N. Engl. J. Med. 2009, 360(21):2176-2190.
50. Simoons M.L. Effect of glycoprotein IIb/IIIa receptor blocker abciximab on outcome in patients with acute coronary syndromes without early coronary revascularisation: the GUSTO IV-ACS randomised trial. Lancet 2001, 357(9272):1915-1924.
51. Kastrati A., Mehilli J., Schuhlen H., et al. A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel. N. Engl. J. Med. 2004, 350(3):232-238.
52. Kastrati A., Mehilli J., Neumann F.J., et al. Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment: the ISAR-REACT 2 randomized trial. JAMA 2006, 295(13):1531-1538.
53. Stone G.W., McLaurin B.T., Cox D.A., et al. Bivalirudin for patients with acute coronary syndromes. N. Engl. J. Med. 2006, 355(21):2203-2216.
54. Kunadian V., Giugliano R.P., Newby L.K., et al. Angiographic outcomes with early eptifibatide therapy in non-ST-segment elevation acute coronary syndrome (from the EARLY ACS Trial). Am. J. Cardiol. 2014, 113(8):1297-1305.